知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

1157 条记录 (耗时 0.032 秒)

    Double-acylated GLP-1 compounds
    81.
    发明授权
    Double-acylated GLP-1 compounds 有权

    公开(公告)号：US10689429B2

    公开(公告)日：2020-06-23

    申请号：US15301960

    申请日：2015-04-07

    申请人： Novo Nordisk A/S

    发明人： Lars Linderoth ,  Jacob Kofoed ,  Jesper Lau ,  Paw Bloch ,  Patrick William Garibay ,  Janos Tibor Kodra

    IPC分类号： C07K14/605 ,  C07C235/20 ,  A61K38/00

    摘要： The invention relates to a derivative of a GLP-1 peptide, which peptide comprises a first Lys residue at a position corresponding to position 36 of GLP-1(7-37) (SEQ ID NO: 1), a second Lys residue at a position corresponding to position 37 of GLP-1(7-37) (SEQ ID NO: 1), and a maximum of seven amino acid changes as compared to GLP-1(7-37) (SEQ ID NO: 1); which derivative comprises two protractors attached to said first and second Lys residue, respectively, each via a linker; wherein the protractor is selected from: HOOC—C6H4—O—(CH2)y—CO—*, and  Chem. 1: HOOC—(CH2)x—CO—*,  Chem. 2: wherein y is an integer in the range of 8-11, and x is 12; and the linker comprises at least one of: *—NH—CH(COOH)—(CH2)2—CO—*,  Chem. 3: *—NH—CH((CH2)2—COOH)—CO—*, and/or  Chem. 4: *—NH—(CH2)2—[O—(CH2)2]k—O—[CH2]n—CO—*,  Chem. 5: wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical uses thereof, such as for the treatment of diabetes and obesity, as well as to the GLP-1 peptides forming part of these derivatives which have Lys residues at positions 36 and 37 and no other Lys residues, and the GLP-1(9-37) fragments thereof. The invention furthermore relates to an intermediate product comprising 3-carboxyphenoxy-nonanoic acid with a protection group at the carboxy group of the nonanoic acid, optionally via a linker. The derivatives have a very good potency and a long half-life which makes them potentially useful for, e.g., oral administration.

    Double-acylated GLP-1 derivatives
    82.
    发明授权
    Double-acylated GLP-1 derivatives 有权

    公开(公告)号：US10604554B2

    公开(公告)日：2020-03-31

    申请号：US15966642

    申请日：2018-04-30

    申请人： Novo Nordisk A/S

    发明人： Jacob Kofoed ,  Patrick William Garibay ,  Jesper Lau

    IPC分类号： C07K14/605 ,  A61K38/26 ,  A61K38/00

    摘要： The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue and a second K residue, at positions corresponding to position 26, and 37, respectively, of GLP-1(7-37) (SEQ ID NO: 1), and a maximum of eight amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1: HOOC—(CH2)x—CO—*, and Chem. 2: HOOC—C6H4—O—(CH2)y—CO—*, in which x is an integer in the range of 8-16, and y is an integer in the range of 6-13; and the linker comprises Chem. 3: *—NH—(CH2)q—CH[(CH2)w—NR1R2]—CO—*, which is connected at its CO—* end to the epsilon amino group of the first or the second K residue of the GLP-1 analogue, and wherein q is an integer in the range of 0-5, R1 and R2 independently represent *—H or *—CH3, and w is an integer in the range of 0-5; or a pharmaceutically acceptable salt, amide, or ester thereof.The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptide and linker intermediates. The derivatives are potent, stable, protracted, and suitable for oral administration.

    Accessory device with snap feature
    83.
    发明授权
    Accessory device with snap feature 有权

    公开(公告)号：US10603442B2

    公开(公告)日：2020-03-31

    申请号：US15505423

    申请日：2015-08-25

    申请人： Novo Nordisk A/S

    发明人： Nikolaj Eusebius Jakobsen ,  Ian McLoughlin

    IPC分类号： A61M5/315 ,  A61M5/20 ,  A61M5/24 ,  G06F19/00

    摘要： A logging device adapted to be attached to a pen drug delivery device (210) and capture a property value related to the dose amount of drug expelled from the drug delivery device during an expelling event, the logging device comprising a bore in which a snap lock with a flexible wire portion is arranged circumferentially in the bore, the wire being adapted to be moved laterally by a projection on the pen device and subsequently snap inwardly when the pen device is inserted axially in the bore. In this way an axial snap lock is provided between the logging device and the drug delivery device.

    Spring-driven drug delivery device
    85.
    发明授权
    Spring-driven drug delivery device 有权

    公开(公告)号：US10596328B2

    公开(公告)日：2020-03-24

    申请号：US15532579

    申请日：2015-12-22

    申请人： Novo Nordisk A/S

    发明人： Christian Plambech ,  Jesper Peter Windum

    IPC分类号： A61M5/315 ,  A61M5/20 ,  A61M5/24 ,  A61M5/31

    摘要： The present invention relates to a drug delivery device (100) comprising a housing (101), a threaded piston rod (102), a rotatable drive tube (103), a drive nut (104) in threaded engagement with the piston rod (102) and being rotationally locked but axially moveable relative to the drive tube (103), and a support member (105) arranged rotationally free on the piston rod (102), the support member (105) being axially locked relative to the housing (101) and arranged to allow the drive tube (103) to move axially. The device further comprises a compression drive spring (106) arranged between the piston rod (102) and the drive tube (103), the compression drive spring (106) being arranged axially between the drive nut (104) and the support member (105).

    Power efficient electronic device
    88.
    发明授权
    Power efficient electronic device 有权

    公开(公告)号：US10556066B2

    公开(公告)日：2020-02-11

    申请号：US15575864

    申请日：2016-05-26

    申请人： Novo Nordisk A/S

    发明人： Andre Larsen

    IPC分类号： A61M5/315 ,  H01M12/06 ,  H01M6/36 ,  A61M5/20 ,  A61M5/31 ,  A61M5/32

    摘要： An assembly comprises an electric consumer, an electric voltage source adapted to power the electric consumer, and user operated actuation means. The electric voltage source is operatable between a first state in which a first voltage is generated and a second state in which a second higher voltage is generated. The user operated actuation means is operatable from a first to a second state and adapted to thereby operate the electric voltage source from the first to the second state, and operatable from the second state to the first state and adapted to thereby operate the electric voltage source from the second to the first state.

    END-OF-CONTENT MECHANISM
    89.
    发明申请
    END-OF-CONTENT MECHANISM 审中-公开

    公开(公告)号：US20200030542A1

    公开(公告)日：2020-01-30

    申请号：US16500991

    申请日：2018-04-06

    申请人： Novo Nordisk A/S

    发明人： Nikolaj Eusebius Jakobsen

    IPC分类号： A61M5/315

    摘要： The present invention provides a drug injection device (1) for delivering multiple doses of drug, comprising: a housing (2) extending along a main axis, a dose expelling mechanism comprising a piston rod (60) configured to move relative to the housing (2) from a first position to a second position to cause ejection of a dose of drug, the piston rod (60) extending between a proximal piston rod end and a distal piston rod end and comprising a dosing track (63), the piston rod (60) further being movable relative to the housing (2) from an initial pre-use position to a final end stop position to cause accumulated ejection of a predefined total dose, a dosing track follower (17) fixed with respect to the housing (2) and adapted to travel the dosing track (63) during dose ejection, a dose setting mechanism operable to set the dose to be ejected by the dose expelling mechanism, electronic means (82, 90, 91, 92, 95) for registering a dose setting operation and for registering a dose size of an ejected dose, and a display (81) adapted to indicate a size of a current set dose, the electronic means (82, 90, 91, 92, 95) being configured to provide a first type of update of the display (81) responsive to dose changing operations of the dose setting mechanism, wherein the electronic means (82, 90, 91, 92, 95) is further configured to calculate a current accumulated dose from the dose sizes of registered ejected doses to thereby provide an updated value of a total amount of drug ejected, determine a current remaining dose by comparing the current accumulated dose and the predefined total dose, and provide a second type of update of the display (81) when during a dose increasing operation of the dose setting mechanism the current set dose exceeds the current remaining dose, the second type of update being different from the first type of update, and wherein the final end stop position is defined by a track end configuration of the dosing track (63) between the proximal piston rod end and the distal piston rod end.

    INJECTION DEVICE WITH TORSION SPRING AND ROTATABLE DISPLAY
    90.
    发明申请
    INJECTION DEVICE WITH TORSION SPRING AND ROTATABLE DISPLAY 审中-公开

    公开(公告)号：US20200030541A1

    公开(公告)日：2020-01-30

    申请号：US16589566

    申请日：2019-10-01

    申请人： Novo Nordisk A/S

    发明人： Claus Schmidt Moeller ,  Tom Hede Markussen ,  Christian Peter Enggaard

    IPC分类号： A61M5/315 ,  A61M5/145 ,  A61M5/20

    摘要： The present invention relates to an injection device comprising a torsion spring operatively connected to a dose setting member being adapted to set a dose to be ejected from the injection device. A rotatably mounted display member adapted to display the dose to be ejected in accordance with a setting of the dose setting member is also provided. The rotatably mounted display member is adapted to be rotated over an angle corresponding to at least one revolution of the display member. The display member may be implemented as a dose indicator barrel having numerals arranged along a helical path on an outer surface thereof, or alternatively, as a counting device having two or more display wheels having numerals arranged on an outer surface thereof.